Comparative Effectiveness Will Likely Move To Cost Matters, Speakers Say
This article was originally published in The Gray Sheet
Executive Summary
Industry efforts to restrict comparative effectiveness research from morphing into outright cost comparisons might be a losing battle, some speakers at last week's AdvaMed meeting suggested
You may also be interested in...
CMS Plans Cost-Cutting Revamp Of Physician Fee Schedule
Faced with a fast-depleting Medicare Trust Fund, CMS officials say a sense of urgency underlies their efforts to find rational ways to cut payments in the Physician Fee Schedule
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.